Abiomed, Inc. is a medical device company headquartered in Danvers, Massachusetts, specializing in cardiovascular support technologies. Founded in 1981, it develops and manufactures temporary mechanical circulatory support devices, including the Impella® family of heart pumps, designed to provide hemodynamic support for patients with severe heart failure, cardiogenic shock, or undergoing high-risk procedures.
Key products include Impella CP for high-risk PCI and cardiogenic shock, Impella 5.5 for extended cardiac support, and Impella RP for right heart failure. The company also offers the Breethe OXY-1 System for cardiopulmonary support and Impella Connect for remote patient monitoring. Acquired by Johnson & Johnson in 2022, Abiomed operates as a standalone business within its MedTech segment, with global offices including Aachen, Germany, and Tokyo, Japan.
